|
|
| Biotech Submits NDA After Risk-Based Mock Inspection | An emerging biotech company recently took a preventative approach to mitigate risks, identify potential concerns before an FDA inspection, and submit their NDA. See how these proactive measures accurately addressed gaps within its application and led to a successful submission. |
|
|
|
|
For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients. |
|
|
|
|
|
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
Connect With Life Science Leader: |
|
|
|